FDA Rebif Decision Expected In March, Serono Says
Executive Summary
Serono has "a big inventory" of the multiple sclerosis therapy Rebif (interferon beta-1a) in anticipation of a spring launch, CFO Jacques Theurillat said during a quarterly earnings call Feb. 13
You may also be interested in...
Serono Rebif 25% Market Share Expected By 2006; Monthly Price Is $1,156
Serono hopes Rebif will capture a quarter of the multiple sclerosis market by 2006, CEO Ernesto Bertarelli told securities analysts during a March 11 conference call
Serono Rebif 25% Market Share Expected By 2006; Monthly Price Is $1,156
Serono hopes Rebif will capture a quarter of the multiple sclerosis market by 2006, CEO Ernesto Bertarelli told securities analysts during a March 11 conference call
Medicare Self-Injectable Drug Coverage Rule Expected By Spring
The Centers for Medicare & Medicaid Services expects to issue a memorandum expanding Medicare coverage for self-injectable pharmaceuticals by spring